ALYREF was originally described as a transcriptional coactivator of the T-cell receptor α gene by binding LEF-1 and acute myeloid leukemia (AML)-1 transcription factors to form an enhancer-stimulating complex [29]. The gene discussed is LEF1; the disease is acute myeloid leukemia.